Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in GIST Patients Resistant or Intolerant to Imatinib and Sunitinib
NCT00718562Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Sep 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00718562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718562.